Gemcitabine HCL Market by Type (Branded and Generic), by Application (Pancreatic Cancer, Breast Cancer, Ovarian Cancer, Non-small-cell Lung Cancer (NSCLC)), by End User (Hospitals, Cancer Centers) - Global Analysis & Forecast 2019-2030

Report ID : 186  |  Published Date : Jan 2020  |  Pages : 160  |  Region : Global  |  Report Code : PH-11





Gemcitabine HCL Market Overview and Introduction

Gemcitabine HCL is a nucleoside analogue that shows anti-tumor properties. It is a white powder that is soluble in water and is injected intravenously in the body. It is a chemotherapy drug that slows down or stops the growth of cancer cells.

The global gemcitabine HCL market is driven by the adoption of unhealthy addictions, such as tobacco, alcohol, etc., leading to cancer, an increase in the global aging population, key players focusing more on the research & development of branded drugs, and promising reimbursement scenarios. According to the World Health Organization (WHO), approximately 22% of the cancer-related deaths are caused by tobacco. The incidences of cancer increase with age, as the tendency of cellular repair mechanism lowers or becomes less effective as a person grows old.

The global gemcitabine HCL market is segmented by type, application, end-user, and region.

Gemcitabine HCL Market By Type

Based on type, the gemcitabine HCL market is segmented into branded and generic segments. The generic segment is estimated to account for the largest market share during the forecast period. This large market share can be attributed to the high demand for generic over branded medicines owing to cost-effectiveness, reliability, and high-quality versions of branded drugs.

Gemcitabine HCL Market By Application

Based on application, the market is segmented into pancreatic cancer, breast cancer, ovarian cancer, Non-Small-Cell Lung Cancer (NSCLC), and others. Pancreatic cancer is estimated to account for the largest market share owing to the number of new cases of pancreatic cancer diagnosed and an increase in geriatric population.

Gemcitabine HCL Market By End User

In terms of end-user, the gemcitabine HCL market is segmented into hospitals, cancer centers, and others. The hospitals segment is anticipated to account for large market share owing to growing healthcare infrastructure and improving healthcare information systems in developing countries.

Gemcitabine HCL Market By Region

By geography, the global gemcitabine HCL market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America will continue to dominate the gemcitabine HCL market followed by Europe and Asia Pacific during the forecast period owing to factors such well-developed healthcare facilities and increasing incidences of cancer.  However, Asia Pacific is expected to witness the highest CAGR, with market growth centered in and around China, Korea, Japan, and India. Factors such as the adoption of cost-effective generic drugs and the availability of proper guidelines for the manufacture of biosimilars to regional players are expected to propel the market growth in this region. Also, the Asia Pacific region offers major growth prospects for key players owing to factors such as access to better healthcare infrastructure, growing consumer disposable income, and upsurge in demand for improved healthcare, and rising medical tourism.

Gemcitabine HCL Market Prominent Players

Some prominent players in the gemcitabine HCL market include Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord Healthcare, Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Medtronic, Biocon, and Cipla Inc., among others.